Swedish severity-based cost-effectiveness threshold framework
A method used in Sweden to decide how much to pay for health treatments based on how severe the disease is and how well the treatment works, using real decisions from the past.
At a glance
Use when
Conducting cost-effectiveness analyses in Sweden; incorporating equity considerations into HTA; evaluating treatments for severe diseases
Avoid when
Applying in countries with different ethical frameworks or funding systems; when severity cannot be clearly defined
Inputs
Disease severity classification, health technology cost and QALY gain
Outputs
Severity-adjusted cost-effectiveness threshold and reimbursement recommendation
How it works
A tiered cost-effectiveness threshold framework developed by TLV (Dental and Pharmaceutical Benefits Agency) that adjusts willingness-to-pay per QALY according to disease severity, empirically derived from historical reimbursement decisions to reflect the needs-solidarity principle in Swedish healthcare.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Organisational aspects
- Assumptions
- Disease severity can be reliably categorized; past reimbursement decisions reflect societal values; willingness-to-pay varies with severity
- Strengths
- Reflects ethical principles of solidarity and need; grounded in real-world decisions; transparent tiered structure
- Limitations
- Severity classification may be subjective; limited generalizability outside Sweden; relies on historical data patterns
Questions this answers
- › How does disease severity affect cost-effectiveness thresholds?
- › What are Sweden's implicit willingness-to-pay per QALY values for different severity levels?
- › How is solidarity incorporated into reimbursement decisions?
- › How are thresholds calibrated from past decisions?
- › Can cost-effectiveness thresholds be ethically justified based on severity?
- › How do tiered thresholds influence drug pricing and access?
References & sources
Similar by meaning
- Norwegian severity classes and severity-weighted cost-effectiveness thresholds (Magnussen approach)
- Swedish Value-Based Pricing reimbursement system (TLV)
- Norwegian Absolute Shortfall severity operationalization (drug reimbursement)
- Hungarian relative-QALY-gain stratified cost-effectiveness threshold framework (1.5-3x GDP)
- Proportional Shortfall
Beta record. Based on the original catalogue summary; primary-source enrichment pending.